Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lupus Erythematosus, Systemic: early-phase trial registry
11 of 30 indexed Lupus Erythematosus, Systemic trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 11 currently recruiting · #519 of 28,707 conditions by registered trial count
Lupus Erythematosus, Systemic: 30 US clinical trials tracked, 11 recruiting.
Lupus Erythematosus, Systemic is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Viatris Innovation, running 3 of these trials.
Enrollment posture brief
Registry condition lupus-erythematosus-systemic
OPEN 11 | RECR 37% | LATE 9 | EARLY 14 | RANK #519 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Bariatric Surgery Candidate (37% recruiting · 30 trials)
Lupus Erythematosus, Systemic lists 11 open slots (37% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lupus Erythematosus, Systemic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lupus Erythematosus, Systemic is recruiting below its size-band peers.
11 of 30 indexed trials (36.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lupus Erythematosus, Systemic trials is spread across many organizations.
Viatris Innovation accounts for 3 of 30 trials (10%). 26 distinct sponsors appear on at least one study for this condition label.
-
Typical Lupus Erythematosus, Systemic enrolment sits around 172 participants.
Median target enrolment is 172 among the 30 trials that report a genuine target (sentinel values excluded). 11 of those (36.7%) plan for fewer than 100 participants.
-
Lupus Erythematosus, Systemic research is mostly interventional.
27 interventional and 3 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Janssen Research & Development
NCT07438496
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Viatris Innovation
NCT05648500
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Viatris Innovation
NCT07201129
Dose Response of Exercise for Arthritis Management
University of South Carolina
NCT06880653
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
Ampel BioSolutions
NCT05845593
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Novartis Pharmaceuticals
NCT06581198
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
AstraZeneca
NCT06897930
Brief Pain Exposure Therapy (BPET) For Nociplastic Pain
University of Michigan
NCT06208514
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT07015983
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
CRISPR Therapeutics
NCT06925542
Trial of Belimumab in Early Lupus
Northwell Health
NCT03543839
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Biogen
NCT04961567
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Biogen
NCT04895241
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Viatris Innovation
NCT05672576
Lupus Intervention for Fatigue Trial
Northwestern University
NCT02653287
Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
Vanderbilt University Medical Center
NCT03527472
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Genentech
NCT00137969
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
Laura Schanberg
NCT00065806
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
MedImmune
NCT01753193
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
Amgen
NCT04925934
Acthar Gel for Active Systemic Lupus Erythematosus (SLE)
Mallinckrodt
NCT02953821
Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients
Qure Healthcare
NCT04266860
A Complex Contraception Registry
University of California, San Diego
NCT02219269
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Janssen Research & Development
NCT02034344
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
Rigel Pharmaceuticals
NCT01597050
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
Pfizer
NCT00714116
Anti-CD20 in Systemic Lupus Erythematosus
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00036491
Phase Ib Study of SC Milatuzumab in SLE
Gilead Sciences
NCT01845740
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
National Cancer Institute (NCI)
NCT00076752
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Joseph B. Ciolino, MD
NCT01582880
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 8 |
| Phase 3 | 7 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Lupus Erythematosus, Systemic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lupus Erythematosus, Systemic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lupus Erythematosus, Systemic page
30 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Lupus Erythematosus, Systemic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Viatris Innovation sponsors the most Lupus Erythematosus, Systemic trials on record, review their full trial history before evaluating a specific study. See Viatris Innovation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lupus Erythematosus, Systemic condition card totals 30 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.